



ASSOCIAZIONE ITALIANA  
CONTRO LEUCEMIE  
LINFOMI E MIELOMA

# LEUKEMIA 2022

Rome, Hotel NH Collection - Vittorio Veneto

May 5-6, 2022

AIL President: P. Toro

Coordinators: A.M. Carella, S. Amadori



AUSPICES:



**fondazione GIMEMA** onlus  
per la promozione e lo sviluppo della ricerca scientifica  
sulle malattie ematologiche. **FRANCO MANDELLI**



GRUPPO ASSOCIATO AIL - ASSOCIAZIONE ITALIANA CONTRO LEUCEMIE LINFOMI E MIELOMA



**SIE - Società Italiana di Ematologia**

# LEUKEMIA2022

Rome, Hotel NH Collection - Vittorio Veneto

May 5-6, 2022

AIL President: P. Toro  
Coordinators: A.M. Carella, S. Amadori

## Welcome message

We welcome you to the 11th annual Conference on "Leukemia 2022". We are very pleased to inform you that the Conference will be held in cooperation with the Italian Association against Leukemia, Lymphomas and Myeloma (AIL), the largest Italian voluntary organization dedicated to funding blood cancer research and patient services. The aim of the Conference is to bring together highly qualified Italian and international scientists and clinicians to discuss emerging paradigms and breakthroughs at the forefront of biology and treatment across the spectrum of blood cancers, including acute and chronic leukemias, myelodysplastic syndromes, myeloproliferative disorders, lymphomas and myelomas. Attendees will hear of recent findings in basic and clinical research, from the molecular basis of blood cancers to novel therapies emerging in the clinic, through ample interaction with key experts in the field.

### SERGIO AMADORI



### ANGELO MICHELE CARELLA



### SCIENTIFIC BOARD

Sergio Amadori  
Angelo M. Carella  
Fabio Ciceri  
Antonio Cuneo  
Fabrizio Pane  
Alessandro Rambaldi  
Valeria Santini  
Alessandro M. Vannucchi

### AIL SCIENTIFIC COMMITTEE

William Arcese  
Fabrizio Pane  
Pier Giuseppe Pelicci  
Francesco Rodeghiero  
Giorgina Specchia

## Faculty

Sergio	AMADORI	Rome, Italy
Renato	BASSAN	Mestre (VE), Italy
Matteo	BERSANELLI	Rozzano (MI), Italy
Francesca	BONIFAZI	Bologna, Italy
Massimo	BRECCIA	Rome, Italy
Francesco	BUCCISANO	Rome, Italy
Angelo Michele	CARELLA	Genoa, Italy
Michele	CAVO	Bologna, Italy
Sabina	CHIARETTI	Rome, Italy
Fabio	CICERI	Milan, Italy
Paolo	CORRADINI	Milan, Italy
Marta	COSCIA	Turin, Italy
Elena	CRISÀ	Novara, Italy
Antonio	CUNEO	Ferrara, Italy
Antonio	CURTI	Bologna, Italy
Valerio	DE STEFANO	Rome, Italy
Ilaria	DEL GIUDICE	Rome, Italy
Matteo G.	DELLA PORTA	Rozzano (MI), Italy
Brunangelo	FALINI	Perugia, Italy
Felicetto	FERRARA	Naples, Italy
Andrés J.M.	FERRERI	Milano, Italy
Robin	FOÀ	Rome, Italy
Matilde Y.	FOLLO	Bologna, Italy
Paolo	GHIA	Milan, Italy
Paola	GUGLIEMELLI	Florence, Italy
Carmelo	GURNARI	Cleveland, USA
Alessandro	ISIDORI	Pesaro
Franco	LOCATELLI	Rome, Italy
Francesco	MANNELLI	Florence, Italy
Giovanni	MARTINELLI	Meldola (FC), Italy
Francesca R.	MAURO	Rome, Italy
Cristina	MECUCCI	Perugia, Italy
Pellegrino	MUSTO	Bari, Italy
Fabrizio	PANE	Naples, Italy
Francesco	PASSAMONTI	Varese, Italy
Giovanni	PIZZOLO	Verona, Italy
Alessandro	PULSONI	Rome, Italy
Alessandro	RAMBALDI	Bergamo, Italy
Luigi	RIGACCI	Rome, Italy
Davide	ROSSI	Bellinzona, Svizzera
Gianantonio	ROSTI	Bologna, Italy
Giovanni	ROTI	Parma, Italy
Giuseppe	SAGLIO	Orbassano (TO), Italy
Valeria	SANTINI	Florence, Italy
Simona	SICA	Rome, Italy
Sergio	SIRAGUSA	Palermo, Italy
Simona	SOVERINI	Bologna, Italy
Mario	TIRIBELLI	Udine, Italy
Pino	TORO	Palermo, Italy
Alessandro M.	VANNUCCHI	Florence, Italy
Adriano	VENDITI	Rome, Italy
Umberto	VITOLO	Turin, Italy
Maria Teresa	VOSO	Rome, Italy
Pier Luigi	ZINZANI	Bologna, Italy



Thursday, May 5, 2022

11.00 am **Greetings from AIL President**

P. Toro

11.15 am **LECTURE**

From biology to therapy: progress in acute promyelocytic leukemia  
Introduced by S. Amadori, A. M. Carella

M.T. Voso

### **SESSION I ACUTE MYELOID LEUKEMIA**

Chairmen: **S. Amadori, S. Sica**

11.30 am Emerging targeted therapies and combinations

A. Venditti

11.45 am Novel strategies to treat older patients

F. Buccisano

12.00 pm Is it maintenance therapy necessary?

A. Isidori

12.15 pm Novel approaches for p53-mutant AML

G. Martinelli

12.30 pm Immune-based therapies: new horizons

A. Curti

12.45 pm *Discussion*

01.00 pm **Break**

### **SESSION II CHRONIC LYMPHOCYTIC LEUKEMIA**

Chairmen: **A. Cuneo, G. Pizzolo**

01.45 pm Update on molecular pathogenesis

D. Rossi

02.00 pm Emerging prognostic/predictive factors

I. Del Giudice

02.15 pm Autoimmune complications

M. Coscia

02.30 pm Lessons from clinical trials

P. Ghia

02.45 pm Salvage therapy

F.R. Mauro

03.00 pm *Discussion*



### **SESSION III MYELOPROLIFERATIVE NEOPLASMS**

Chairmen: **V. De Stefano, A.M. Vannucchi**

03.15 pm Post-MPN acute leukemia:  
a persistently unmet need

P. Guglielmelli

03.30 pm Re-assessing the treatment paradigm of PV

V. De Stefano

03.45 pm Thrombosis and bleeding: rationale and  
therapeutic perspectives

S. Siragusa

04.00 pm Beyond JAK inhibitors in MF

F. Passamonti

04.15 pm Hypereosinophilias with and without genetic  
rearrangement

F. Mannelli

04.30 pm *Discussion*

04.45 pm **Break**

### **JOHN GOLDMAN LECTURE**

NPM1 - Mutated AML: from bench to bedside  
Introduced by A.M. Carella

B. Falini

### **SESSION IV CHRONIC MYELOID LEUKEMIA**

Chairmen: **F. Pane, G. Saglio**

05.30 pm Moving beyond the Sokal and ELTS scores:  
baseline molecular factors in CML prognostic

S. Soverini

05.45 pm Imatinib versus a 2nd generation TKI for the first  
line of therapy: how we can tip the balance  
between efficacy and quality of life

M. Tiribelli

06.00 pm The new guidelines for the management of CML

G. Rosti

06.15 pm Future perspectives of novel therapies

M. Breccia

06.30 pm *Discussion*



Friday, May 6, 2022

**SESSION V ACUTE LYMPHOBLASTIC LEUKEMIA**

Chairmen: **R. Foà, A. Rambaldi**

08.30 am	New insights in T/Myeloid mixed-phenotype acute Leukemia (T/M MPAL)	C. Mecucci
08.45 am	Can we predict the chemosensitivity of ALL?	G. Roti
09.00 am	MRD driven strategy in Adult ALL	R. Bassan
09.15 am	New treatment strategies for Ph-like ALL	S. Chiaretti
09.30 am	New treatment strategies in Ph-Negative ALL?	F. Ferrara
09.45 am	Novel Allo-transplant options in adult ALL	F. Bonifazi
10.00 am	Current status and future perspectives on the role of CAR-T cells in childhood ALL	F. Locatelli
10.20 am	<i>Discussion</i>	

**SESSION VI MYELOYDYSPLASTIC SYNDROMES**

Chairmen: **P. Musto, V. Santini**

10.50 am	Recent advances in somatic mutations and altered signaling in MDS cell	M.Y. Follo
11.05 am	Towards a new prognostication of MDS	M. Bersanelli
11.20 am	Artificial Intelligence to improve clinical decision making in hematological malignancies	M.G. Della Porta
11.35 am	Is it possible to stop therapy in MDS (high risk vs low risk)?	E. Crisà
11.50 am	Vexas syndrome and myelodysplastic syndromes	C. Gurnari
12.05 pm	<i>Discussion</i>	

**SESSION VII EXPANDING HORIZONS FOR IMMUNOTHERAPY IN ONCO-HEMATOLOGY**

Chairmen: **F. Ciceri, L. Rigacci**

12.20 pm	State of the art	A.J.M. Ferreri
12.35 pm	CAR-T in Large B cell NHL	P. Corradini
12.50 pm	CAR-T in Indolent NHL	A. Pulsoni
01.05 pm	New recombinant antibodies in Lymphomas	P.L. Zinzani
01.20 pm	New Drugs in NHLs	U. Vitolo
01.35 pm	Next generation immunotherapy in Multiple Myeloma	M. Cavo
01.50 pm	<i>Discussion</i>	
02.10 pm	<b>Closing Remarks</b>	
02.15 pm	<b>Light Lunch</b>	

with unrestricted educational grant of:



## GENERAL INFORMATION

### MEETING VENUE

#### NH Hotel Vittorio Veneto

Corso d'Italia, 1 - 00198 Rome, Italy

Phone +39 06 84951

### OFFICIAL LANGUAGE

The official language of the congress will be the Italian.

### REGISTRATION

The registration is free. It is possible to register on the website [www.ercongressi.it](http://www.ercongressi.it), section Congressi/2022.

### BADGE AND CERTIFICATE OF ATTENDANCE

All registered participants and speakers will be given a badge which must be worn to be admitted to the scientific sessions.

A certificate will be given to all participants at the end of the meeting.

### ITALIAN CME CREDITS

An Italian CME application has been submitted as follows:

- Provider Studio ER Congressi SRL: ID 828-282400.
- No. **9,1 CME** credits for Physicians (disciplines: Hematology, Oncology, Clinical pathology, Internal Medicine) and Biologists.
- Educational objective: "linee guida-protocolli-procedure".

### CHANGES

Parts of the program may be changed without notice.

## ORGANIZING SECRETARIAT

### Studio E.R. Congressi

Via De' Poeti, 1/7 - 40124 Bologna, Italy

Ph +39 051 4210559 - Fax +39 051 4210174

E-mail: [ercongressi@ercongressi.it](mailto:ercongressi@ercongressi.it)

[www.ercongressi.it](http://www.ercongressi.it)